VOLITIONRX LTD Annual Report: A Simple Guide

I’ve put together this guide to help you understand how VolitionRx performed this year. Instead of digging through dense legal filings, we’ll break down the business so you can decide if it fits your portfolio.

1. What does this company do?

VolitionRx is a diagnostics company focused on "epigenetics." They study the "formatting" of DNA to spot diseases like cancer and sepsis early. Think of DNA as an instruction manual; Volition looks for the highlights that indicate a disease is brewing before a patient feels sick.

They are currently in a growth phase, focusing on getting products into labs rather than turning a profit. Their core platform, Nu.Q®, uses proprietary technology to detect nucleosomes in the blood, offering a non-invasive alternative to traditional biopsies.

2. Financial performance

The company is in the early stages of generating sales. For 2023, VolitionRx reported $1.1 million in revenue, up from $0.6 million in 2022. They reached a milestone in early 2025 by recording their first revenue from a clinically approved product in Europe.

They use a licensing model, partnering with giants like Werfen, Hologic, and IDEXX to distribute their tests rather than building a massive internal sales force. Their 2023 loss was $28.5 million, reflecting heavy spending on research and clinical trials.

3. Major wins this year

• Veterinary Success: The Nu.Q® Vet cancer test is now available in over 20 countries. They also signed an automation deal with Fujifilm, allowing their tests to run on high-speed lab machines.
• Human Diagnostics: They are moving into lung cancer screening, with plans to launch in France by late 2026.
• New Tech: Their "Capture-PCR/Seq" technology makes detecting cancer DNA cheaper and faster by isolating it from "background noise" in the blood.
• Intellectual Property: They hold 68 patents worldwide, protecting their technology through at least 2045.

4. Financial health

The company is balancing its finances carefully. They held about $11.5 million in cash as of their last report. They have over 25.8 million outstanding warrants; if these are exercised, the company gains $14.7 million, though this would increase the total share count and dilute current ownership. They have reduced staff from 85 to 75 to save money, aiming to extend their cash runway until 2026.

5. Key risks

The auditors have issued a "going concern" opinion, which highlights uncertainty regarding the company's ability to continue operations without raising additional capital. They also face strict regulatory hurdles; if they fail to meet quality standards, they cannot sell their products. Furthermore, they operate in a competitive landscape against well-funded firms with similar technologies.

6. Future outlook

Volition’s strategy relies on their tests becoming the preferred choice for doctors due to their low cost and compatibility with existing hospital equipment. Success depends on navigating complex regulations and securing insurance reimbursement. With a monthly burn rate of $2 million, the company must prioritize sales growth or secure additional funding.

Investor Takeaway: VolitionRx is a high-risk, high-reward play. You are betting on their ability to scale their licensing model and secure regulatory approvals before their current cash reserves run dry. If you are considering an investment, keep a close eye on their quarterly cash burn and progress toward commercial insurance coverage.